Strategic focus Limited headcount but strong niche focus on novel PET imaging agents for cardiovascular disease, oncology, and neurology, signaling partnerships and outsourcing potential with CROs and academic collaborators to scale R&D and clinical validation.

Funding leverage Recent funding and a 1M-10M revenue range indicate available capital for strategic partnerships, licensing deals, or co-development arrangements with larger biotech and imaging companies seeking to augment their PET tracer portfolios.

Academic collaborations Technology platform developed with Massachusetts General Hospital and Harvard Medical School presents credibility and pathways for co-development, sponsored research, or licensing of proprietary imaging agents to expand market reach.

Market opportunity Focus on acute and chronic coronary artery disease and inflamed atherosclerotic plaque suggests opportunities to target cardiology incumbents and imaging device manufacturers seeking new contrast agents and companion diagnostics.

Digital footprint Tech stack and online presence indicate room to enhance digital marketing and lead generation through search optimization, thought leadership, and CRO/academic engagement portals to attract collaboration opportunities.